Agios Pharmaceuticals' Tibsovo (ivosidenib) Receives Approval For R/R Acute Myeloid Leukemia (AML) and IDH1 Mutation
Shots:
- The approval is based on P-I AG120-C-011 (NCT02074839) study results assessing Tibsovo (ivosidenib- 500mg) in 174 patients with r/r AML and IDH1 mutation aged 67 yrs.
- P-I AG120-C-011 study results: CR+CRh rate 32.8%; CR rate 24.7%; median CR+CRh 8.2 mos.; median time to best response of CR or CRh 2.0mos.; median duration to exposure 3.9mos.; 41/110 (37.3%) patient became independent from RBC or platelet transfusion; 21/174 (12%) are on stem cell transplantation + Tibsovo treatment
- Tibsovo (ivosidenib- 500mg) is a novel PO isocitrate dehydrogenase-1 (IDH1) inhibitor targeted for r/r AML with IDH1 mutation
Ref: Agios | Image: The Street
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com